Transcatheter Embolization and Occlusion Devices Market : Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2028

 

Transcatheter embolization and occlusion are terms used to describe the passage or insertion of a synthetic embolus through a fine catheter in a blood vessel to obstruct the blood flow in a specific area of the body. Transcatheter embolization is a minimally invasive technique used in interventional radiology to stop the flow of blood to tumors. Chemotherapeutic drugs that perform a dual action of obstructing the blood supply and inducing cytotoxicity in order to attack the tumor in various ways are sometimes coated on synthetic materials known as embolic agents. Additionally, this procedure is used to treat aneurysms, which are weak arterial sacs or bulges that form abnormal connections between arteries and veins, control or prevent abnormal bleeding, and eliminate those connections.

A variety of gynecologic and obstetric abnormalities can benefit from transcatheter embolization as a treatment option. With the help of radiologic imaging for guidance, Transcatheter Embolization and Occlusion Devices Market procedures can be carried out without surgery and with minimal morbidity and mortality, preserving a patient's future fertility potential.

Transcatheter Embolization and Occlusion Devices Market can be carried out for the treatment of a variety of lesions in the female pelvis, including obstetric-gynecologic hemorrhage, advanced-stage malignancy, ectopic pregnancy, and arteriovenous malformation, under the guidance of experienced interventional radiologists and crucial technical support. In addition, it can be used to treat symptomatic uterine fibroids and pelvic congestion syndrome in women who have undergone the necessary screening.

Transcatheter Embolization and Occlusion Devices Market is a helpful technique in the therapeutic management of patients with vascular injuries brought on by percutaneous procedures, liver surgery, or trauma. While such injuries are uncommon, the presence of hemobilia or hemoperitoneum due to a pseudoaneurysm or blood vessel laceration could put a patient in grave danger. Despite an associated morbidity of 58% that is primarily related to bile leakage, liver abscesses, and/or necrosis, selective embolization of the injury produces excellent results in terms of hemostasis (86%).

Key Players

Boston Scientific Corporation, Terumo Corporation, Cook Medica, DePuy Synthes, Edwards, Eisai, Medtronic Plc, Merit Medical System, Stryker Corporation, St. Jude Medical, and Pfizer, Inc. are important market participants in the transcatheter embolization and occlusion devices market.